Estudio SHARP 1 Implicaciones en la Prevención 2ª de la Cardiopatía Isquémica 1 José R. González Juanatey Área Cardiovascular. Hospital Clínico Universitario de Santiago de Compostela J.R.G. JUANATEY C.H.U.Santiago Ezetimibe 2011 Cuestiones pendientes Eficacia Seguridad Nefroprotección J.R.G. JUANATEY C.H.U.Santiago J.R.G. JUANATEY C.H.U.Santiago EU, Total Cholesterol Goal % patients in 2P Total cholesterol >4.5 mMol/L (175 mg/dL) EUROASPIRE III J.R.G. JUANATEY C.H.U.Santiago J.R.G. JUANATEY C.H.U.Santiago J.R.G. JUANATEY C.H.U.Santiago Intima-Media Thickness of the Carotid Artery during 24 and 14 Months of Therapy ENHANCE-Trial ARBITER-6 HALTS Kastelein J et al. N Engl J Med 2008;358:1431-1443 J.R.G. JUANATEY C.H.U.Santiago Taylor A et al. N Engl J Med 2009;361:2113-2122 Ezetimibe “During the trial, investigators reported an increased number of cancers and cancerrelated deaths in patients using Vytorin compared to placebo. Cancer was reported in 105 patients (11.1%) in the Vytorin group and in 70 patients (7.5%) in the placebo group. The number of deaths from cancer was also higher in the Vytorin group, with 39 deaths compared to 23 deaths in the placebo group. A large body of long-term clinical data indicates that simvastatin is not associated with an increased risk of cancer, but long-term clinical data on ezetimibe is insufficient to definitely rule out a cancer risk at this time.” J.R.G. JUANATEY C.H.U.Santiago FDA Statement 22. 12. 2009 Alternativas en práctica clínica J.R.G. JUANATEY C.H.U.Santiago de qué estamos pendientes… J.R.G. JUANATEY C.H.U.Santiago Ezetimibe 2011 Cuestiones pendientes Eficacia Seguridad Nefroprotección J.R.G. JUANATEY C.H.U.Santiago SHARP: Principales eventos isquémicos 25 Ratio de riesgo 0.83 (0.74 – 0.94) Logrank 2P=0.0022 Porcentaje de eventos (%) 20 Placebo 15 Eze/simv 10 5 0 0 1 2 3 Años de seguimiento J.R.G. JUANATEY C.H.U.Santiago 4 5 CTT: Efectos sobre los eventos isquémicos Reducción de riesgo relativo de eventos isquémicos (95% CI) 30% Estatinas vs control (21 estudios) Tratamiento hipolipemiante intensivo vs convencional (5 estudios) 25% 20% SHARP 17% de reducción SHARP de riesgo 15% 10% 32 mg/dL 5% 0% 0 J.R.G. JUANATEY C.H.U.Santiago 10 20 30 Diferencia media de cLDL entre los grupos tratados (mg/dL) 40 Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis Kaplan–Meier Curves for Primary and Secondary Outcomes and Death Death from Any cause Placebo Hazard ratio, 0.78 Simvastatin plus ezetimible P=0.02 Percentage of Patients Percentage of Patients Ischemic Cardiovascular Events Simvastatin plus ezetimible Hazard ratio, 1.04 P=0.80 Placebo Years in Study Years in Study No. at Risk No. at Risk Simvastatin plus ezetimible 917 867 823 769 76 Simvastatin plus ezetimible 930 912 884 855 89 Placebo 898 838 788 729 76 Placebo 916 890 865 835 94 J.R.G. JUANATEY C.H.U.Santiago Rossebo AB et al. N Engl J Med 2008;359 Meta-análisis Hipolipemiantes Reducción Proporcional en Índice de Enfermedades (SE) Ez/Sim - Eficacia Enfermedades Coronarias Mayores 50 40 Enfermedades Vasculares Mayores 50 SPARCL-A -35 40 30 SHARP Ez/Sm (26.3%) 30 SPARCL-A -20 20 20 SHARP Ez/Sm (16.1%) 10 10 Ictus -16 -1.58 -1.58 0 -10 0 0,5 1,0 1,5 2,0 0,5 1,0 1,5 -10 Reducción colesterol LDL (mmol/L) Lancet 2006, 2010 J.R.G. JUANATEY C.H.U.Santiago 2,0 CTT: Efectos sobre los eventos isquémicos CV Protection in CKD Pt Reducción de riesgo relativo de eventos isquémicos (95% CI) 30% 25% 20% Estatinas vs control (21 estudios) Tratamiento hipolipemiante intensivo vs convencional (5 estudios) SHARP 17% de reducción SHARP de riesgo 15% 10% 32 mg/dL 5% Baseline: 0% CT 0189+45 mg/dl 10 J.R.G. JUANATEY C.H.U.Santiago 20 30 Diferencia media de cLDL LDL-C 108+34 mg/dl entre los grupos tratados (mg/dL) 40 AURORA 4% de reducción de riesgo Alternativas en práctica clínica SHARP J.R.G. JUANATEY C.H.U.Santiago Ezetimibe 2011 Cuestiones pendientes Eficacia Seguridad Nefroprotección J.R.G. JUANATEY C.H.U.Santiago Porcentaje de pacientes que desarrollan cácer (%) SHARP: Incidencia de Cáncer 25 20 Risk ratio 0.99 (0.87 – 1.13) Logrank 2P=0.89 15 Eze/simv Placebo 10 5 0 0 1 2 3 Años de seguimiento J.R.G. JUANATEY C.H.U.Santiago 4 5 SHARP: Seguridad Miopatía CK >10 x y ≤40 x ULN CK >40 x ULN Hepatitis Aumento continuado ALT/AST >3x ULN Complicaciones por cálculos biliares Otras hospitalizaciones por cálculos biliares Pancreatitis sin cálculos biliares J.R.G. JUANATEY C.H.U.Santiago Eze/simv Placebo (n=4650) (n=4620) 17 (0.4%) 4 (0.1%) 21 (0.5%) 30 (0.6%) 85 (1.8%) 21 (0.5%) 16 (0.3%) 5 (0.1%) 18 (0.4%) 26 (0.6%) 76 (1.6%) 30 (0.6%) 12 (0.3%) 17 (0.4%) Ezetimibe “During the trial, investigators reported an increased number of cancers and cancerrelated deaths in patients using Vytorin compared to placebo. Cancer was reported in 105 patients (11.1%) in the Vytorin group and in 70 patients (7.5%) in the placebo group. The number of deaths from cancer was also higher in the Vytorin group, with 39 deaths compared to 23 deaths in the placebo group. A large body of long-term clinical data indicates that simvastatin is not associated with an increased risk of cancer, but long-term clinical data on ezetimibe is insufficient to definitely rule out a cancer risk at this time.”? J.R.G. JUANATEY C.H.U.Santiago FDA Statement 22. 12. 2009 Ezetimibe 2011 Cuestiones pendientes Eficacia Seguridad Nefroprotección J.R.G. JUANATEY C.H.U.Santiago SHARP: Datos sobre parámetros Renales Eventos Evento renal principal Estadío final de Enfermedad Renal (ESRD) Eventos renales secundarios ESRD o muerte ESRD o 2x Cr Eze/simv (n=3117) Placebo (n=3130) 1057 (33.9%) 1084 (34.6%) 0.97 (0.89-1.05) 1477 (47.4%) 1513 (48.3%) 0.97 (0.90-1.04) 1190 (38.2%) 1257 (40.2%) 0.94 (0.86-1.01) Risk ratio & 95% CI 0.6 0.8 1.0 Eze/simv mejor J.R.G. JUANATEY C.H.U.Santiago 1.2 1.4 Placebo mejor Alternativas en práctica clínica SHARP J.R.G. JUANATEY C.H.U.Santiago Ezetimibe 2011 Cuestiones pendientes Eficacia Seguridad Nefroprotección J.R.G. JUANATEY C.H.U.Santiago